Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

The abstract describes 876 participants taking part.

The age groups tagged for this paper are adults, women only.

876 participants with polycystic ovary syndrome undergoing in vitro fertilisation.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

More than one site took part, so the participants came from several places.

Multicentre, double blind, placebo controlled, randomised clinical trial.

24 fertility centres in China.

What Was Measured

PubMed files the paper under topics including China, Dietary Supplements, Fertilization in Vitro, Infertility, Female, Live Birth, Ovarian Hyperstimulation Syndrome and Polycystic Ovary Syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 876 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (BMJ (Clinical research ed.)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.